• USA Home
  • C6022 - Cyproheptadine hydrochloride sesquihydrate

EMAIL THIS PAGE TO A FRIEND
C6022 Sigma-Aldrich

Cyproheptadine hydrochloride sesquihydrate

≥98% (TLC), solid

Synonym: Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-, hydrochloride, hydrate (2:3)

  • CAS Number 41354-29-4

  • Empirical Formula (Hill Notation) C21H21N·HCl·1.5H2O

  • Molecular Weight 350.88

  •  EC Number 213-535-1

  •  PubChem Substance ID 24278082

Purchase

Properties

Related Categories Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bioactive Small Molecules, Biochemicals and Reagents,
assay   ≥98% (TLC)
form   solid
color   white to slightly yellow
solubility   ethanol: soluble
  methanol: soluble
originator   Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES string   Cl.CN1CCC(\CC1)=C2/c3ccccc3C=Cc4ccccc24
InChI   1S/2C21H21N.2ClH.3H2O/c2*1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;;;;;/h2*2-11H,12-15H2,1H3;2*1H;3*1H2
InChI key   ZEAUHIZSRUAMQG-UHFFFAOYSA-N
Gene Information   human ... HRH1(3269), HTR2A(3356), HTR2B(3357), HTR2C(3358)

Description

Application

Cyproheptadine hydrochloride sesquihydrate has been used in:
• testing anti-inflammatory activity in serotonin receptor (5-HT) induced inflammation
• the inhibition of 5-HT in in vivo and in vitro bioassays in crabs
• the inhibition of 5-HT in embryo physiological experiments

inhibition of calcitonin gene related peptide (CGRP)

Packaging

1 g in poly bottle

100 mg in poly bottle

Biochem/physiol Actions

Cyproheptadine hydrochloride sesquihydrate is a serotonin receptor (5-HT2/5-HT1C) antagonist, H1 histamine receptor antagonist and an antipruritic. The inhibition of 5-HT by cyproheptadine improves cognitive function in schizophrenia disorder. Cyproheptadine is effective for treating functional gastrointestinal disorders (FGIDs). Food and Drug Administration (FDA) approved cyproheptadine, has antidepressant and antiplatelet functionality. It may be effective in treating thromboembolic disorders. Cyproheptadine inhibits lysine methyltransferase 7/9 (Set7/9) leading to a decrease in estrogen receptor (ERα) expression and growth arrest in breast cancer cells.

Features and Benefits

This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

Safety & Documentation

Safety Information

Symbol 
GHS06  GHS06
Signal word 
Danger
Hazard statements 
Target organs 
Respiratory system
Personal Protective Equipment 
RIDADR 
UN 2811 6.1 / PGIII
WGK Germany 
WGK 3
RTECS 
TM7050000

Documents

Certificate of Analysis (COA)

Please Enter a Lot Number

Certificate of Origin (COO)

Please Enter a Lot Number
Protocols & Articles
Peer-Reviewed Papers
15

References

Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?